Durable response to olaparib combined low-dose cisplatin in advanced hepatocellular carcinoma with FANCA mutation: A case report
Open Access
- 30 September 2022
- journal article
- research article
- Published by Wolters Kluwer Health in Medicine
- Vol. 101 (39) , e30719
Abstract
Rationale: To date, there is no actionable gene has been discovered in hepatocellular carcinoma (HCC). Tumor cells with DNA damage response and repair (DDR) gene loss-of-function mutation is sensitivity to poly-ADP-ribose polymerase (PARP) inhibitors and platinum chemotherapy in ovarian, prostate and pancreatic cancers. There is a case report demonstrated the efficacy of PARP inhibitor for BRCA2 mutation that belongs to DDR gene in HCC, which suggested the potential role of PARP inhibitor for HCC with DDR gene mutation. Patient concerns: We reported a 44-year-old woman with non-viral HCC who was refractory to multiple treatment including target therapy, immunotherapy, and chemotherapy. The tumor tissue was submitted to next-generation sequencing using the commercially available ACTOnco®+ (ACT Genomics, Taiwan) assay that interrogates 440 and 31 cancer-related genes and fusion genes, respectively. Diagnosis: A truncating mutation FANCA p.Q1307fs was also observed. The tumor was microsatellite stable and had low tumor mutational burden of 4.5 muts/Mb. Interventions and outcomes: Given FANCA belongs to DDR genes, the inactivation evoked the idea of using PARP inhibitor and cisplatin. Therefore, the patient started to use olaparib combined with low-dose cisplatin (30 mg/m2, every 4 weeks) therapy in December 2019. Significant reduction in the tumor marker level in 1 month (PIVKA-II from 17,395 to 411 ng/dL) and follow-up CT scan showed stable disease. Her tumor did not progress until December 2020 with a progression-free survival of 12 months. Lessons: We report the first case of FANCA-mutated HCC that responded well to olaparib and low-dose cisplatin. This addressed the potential therapeutic role of DDR gene mutation in HCC and the possible synergistic effect of PARP inhibitor and cisplatin. These findings highlight areas where further investigation and effort are needed.Keywords
This publication has 14 references indexed in Scilit:
- Olaparib for Metastatic Castration-Resistant Prostate CancerNew England Journal of Medicine, 2020
- Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian CancerNew England Journal of Medicine, 2018
- Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genesBritish Journal of Cancer, 2018
- Preliminary results from TRITON2: A phase II study of rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination repair (HRR) gene alterationsAnnals of Oncology, 2018
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trialThe Lancet Oncology, 2017
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA MutationNew England Journal of Medicine, 2017
- DNA-Repair Defects and Olaparib in Metastatic Prostate CancerNew England Journal of Medicine, 2015
- Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trialThe Lancet Oncology, 2015
- Regulation of DNA cross-link repair by the Fanconi anemia/BRCA pathwayGenes & Development, 2012
- The DNA damage response and cancer therapyNature, 2012